Last updated on February 2018

Nilotinib Peg-IFN for First Line Chronic Phase CML Patients

Brief description of study

This is a phase III trial comparing, for newly diagnosed chronic phase CML patients, nilotinib 600 mg BID as a standard arm and nilotinib 600 mg BID combined to interferon alfa 2 a (pegylated form improving tolerance and maybe enhancing is efficacy) at increased doses for a total of 24 months of combination, in a 1:1 randomized manner. The assessment for the primary efficacy endpoint will be performed at 12 months (since nilotinib initiation) and is the rate patients obtaining MR4.5 will be measured at this time point.

Clinical Study Identifier: NCT02201459

Contact Investigators or Research Sites near you

Start Over

Franck Nicolini, MD

Lyon, France
  Connect »